The mood stabilizer lithium potentiates the antidepressant-like effects and ameliorates oxidative stress induced by acute ketamine in a mouse model of stress

International Journal of Neuropsychopharmacology

Volumn 18, Issue 6, 2015, Pages

  Chiu, Chi Tso ^a   Scheuing, Lisa ^a   Liu, Guangping ^a   Liao, Hsiao Mei ^a   Linares, Gabriel R ^a   Lin, Dora ^a   Chuang, De Maw ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

BDNF; GSK 3; Ketamine; Lithium; mTOR

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; BRAIN DERIVED NEUROTROPHIC FACTOR RECEPTOR; CATALASE; DRINKING WATER; ELONGATION FACTOR 2; GLUTATHIONE DISULFIDE; GLYCOGEN SYNTHASE KINASE 3BETA; KETAMINE; LITHIUM CHLORIDE; MAMMALIAN TARGET OF RAPAMYCIN; POSTSYNAPTIC DENSITY PROTEIN 95; REACTIVE OXYGEN METABOLITE; ANTIDEPRESSANT AGENT; ANTIOXIDANT; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, MOUSE; MTOR PROTEIN, MOUSE; PROTEIN KINASE INHIBITOR; TARGET OF RAPAMYCIN KINASE; TRANQUILIZER;

AEROBIC METABOLISM; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIDEPRESSANT ACTIVITY; ARTICLE; CELL DENSITY; CHRONIC STRESS; CONTROLLED STUDY; CORPUS STRIATUM; DENDRITIC SPINE; DENDRITIC SPINE DENSITY; ENZYME ACTIVITY; HIPPOCAMPUS; IMMOBILITY; IMMOBILIZATION STRESS; LIPID PEROXIDATION; LOCOMOTION; LONG TERM CARE; MALE; MEDIAL PREFRONTAL CORTEX; MOUSE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TAIL SUSPENSION TEST; UPREGULATION; AFFECT; ANIMAL; ANIMAL BEHAVIOR; ANTAGONISTS AND INHIBITORS; DEPRESSION; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; IMMOBILIZATION; MENTAL STRESS; METABOLISM; MOTOR ACTIVITY; PREFRONTAL CORTEX; PSYCHOLOGY; TIME FACTOR;

AFFECT; ANIMALS; ANTIDEPRESSIVE AGENTS; ANTIMANIC AGENTS; ANTIOXIDANTS; BEHAVIOR, ANIMAL; BRAIN-DERIVED NEUROTROPHIC FACTOR; DENDRITIC SPINES; DEPRESSION; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HINDLIMB SUSPENSION; KETAMINE; LITHIUM CHLORIDE; MALE; MICE; MOTOR ACTIVITY; OXIDATIVE STRESS; PREFRONTAL CORTEX; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; STRESS, PSYCHOLOGICAL; TIME FACTORS; TOR SERINE-THREONINE KINASES;

EID: 84981484055     PISSN: 14611457     EISSN: 14695111     Source Type: Journal    
DOI: 10.1093/ijnp/pyu102     Document Type: Article

References (53)

1. Adell A, Castro E, Celada P, Bortolozzi A, Pazos A, Artigas F (2005) Strategies for producing faster acting antidepressants. Drug Discov Today 10:578-585.
2. American Psychiatric A (2002) Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry 159:1-50.
3. Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, Kava-lali ET, Monteggia LM (2011) NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
4. Beaulieu JM, Marion S, Rodriguiz RM, Medvedev IO, Sotnikova TD, Ghisi V, Wetsel WC, Lefkowitz RJ, Gainetdinov RR, Caron MG (2008) A beta-arrestin 2 signaling complex mediates lithium action on behavior. Cell 132:125-136.
5. Berman RM, Cappiello A, Anand A, Oren DA, Heninger GR, Char-ney DS, Krystal JH (2000) Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 47:351-354.
6. Beurel E, Song L, Jope RS (2011) Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice. Mol Psychiatry 16:1068-1070.
7. Browne CA, Lucki I (2013) Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants. Front Pharmacol 4:161.
8. Carlberg U, Nilsson A, Nygard O (1990) Functional properties of phosphorylated elongation factor 2. Eur J Biochem 191:639-645.
9. Carrier N, Kabbaj M (2013) Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology 70:27-34.
10. Chiu CT, Chuang DM (2010) Molecular actions and therapeutic potential of lithium in preclinical and clinical studies of CNS disorders. Pharmacol Ther 128:281-304.
11. Chiu CT, Wang Z, Hunsberger JG, Chuang DM (2013) Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev 65:105-142.
12. Cipriani A, Pretty H, Hawton K, Geddes JR (2005) Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 162:1805-1819.
13. Cryan JF, Mombereau C, Vassout A (2005) The tail suspension test as a model for assessing antidepressant activity: review of pharmacological and genetic studies in mice. Neurosci Biobehav Rev 29:571-625.
14. da Silva FCC, do Carmo de Oliveira Cito M, da Silva MIG, Moura BA, de Aquino Neto MR, Feitosa ML, de Castro Chaves R, Macedo DS, de Vasconcelos SMM, de França Fonteles MM, de Sousa FCF (2010) Behavioral alterations and pro-oxidant effect of a single ketamine administration to mice. Brain Res Bull 83:9-15.
15. de Araujo FY, de Oliveira GV, Gomes PX, Soares MA, Silva MI, Carvalho AF, de Moraes MO, de Moraes ME, Vasconcelos SM, Viana GS, de Sousa FC, Macedo DS (2011) Inhibition of keta-mine-induced hyperlocomotion in mice by the essential oil of Alpinia zerumbet: possible involvement of an antioxidant effect. J Pharm Pharmacol 63:1103-1110.
16. de Oliveira L, Spiazzi CM, Bortolin T, Canever L, Petronilho F, Mina FG, Dal-Pizzol F, Quevedo J, Zugno AI (2009) Different sub-anesthetic doses of ketamine increase oxidative stress in the brain of rats. Prog Neuropsychopharmacol Biol Psychiatry 33:1003-1008.
17. Dehpour AR, Farsam H, Azizabadi-Farahani M (1995) Inhibition of the morphine withdrawal syndrome and the development of physical dependence by lithium in mice. Neuropharmacol-ogy 34:115-121.
18. Dehpour AR, Sadr SS, Azizi MR, Namiranian K, Farahani M, Javidan AN (2002) Lithium inhibits the development of physical dependence to clonidine in mice. Pharmacol Toxicol 90:89-93.
19. DiazGranados N, Ibrahim LA, Brutsche NE, Ameli R, Henter ID, Luckenbaugh DA, Machado-Vieira R, Zarate CA Jr (2010) Rapid resolution of suicidal ideation after a single infusion of an N-methyl-D-aspartate antagonist in patients with treatment-resistant major depressive disorder. J Clin Psychiatry 71:1605-1611.
20. Dwyer JM, Duman RS (2013) Activation of mammalian target of rapamycin and synaptogenesis: role in the actions of rapid-acting antidepressants. Biol Psychiatry 73:1189-1198.
21. Fontella FU, Siqueira IR, Vasconcellos AP, Tabajara AS, Netto CA, Dalmaz C (2005) Repeated restraint stress induces oxidative damage in rat hippocampus. Neurochem Res 30:105-111.
22. Frey BN, Valvassori SS, Reus GZ, Martins MR, Petronilho FC, Bar-dini K, Dal-Pizzol F, Kapczinski F, Quevedo J (2006) Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J Psychiatry Neurosci 31:326-332.
23. Fukumoto T, Morinobu S, Okamoto Y, Kagaya A, Yamawaki S (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychop-harmacology (Berl) 158:100-106.
24. Garcia LS, Comim CM, Valvassori SS, Reus GZ, Barbosa LM, Andreazza AC, Stertz L, Fries GR, Gavioli EC, Kapczinski F, Quevedo J (2008) Acute administration of ketamine induces antidepressant-like effects in the forced swimming test and increases BDNF levels in the rat hippocampus. Prog Neu-ropsychopharmacol Biol Psychiatry 32:140-144.
25. Ghasemi M, Sadeghipour H, Poorheidari G, Dehpour AR (2009) A role for nitrergic system in the antidepressant-like effects of chronic lithium treatment in the mouse forced swimming test. Behav Brain Res 200:76-82.
26. Gunduz-Bruce H (2009) The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res Rev 60:279-286.
27. Hayase T, Yamamoto Y, Yamamoto K (2006) Behavioral effects of ketamine and toxic interactions with psychostimulants. BMC Neurosci 7:25.
28. Ibrahim L, Diazgranados N, Franco-Chaves J, Brutsche N, Henter ID, Kronstein P, Moaddel R, Wainer I, Luckenbaugh DA, Manji HK, Zarate CA Jr (2012) Course of improvement in depressive symptoms to a single intravenous infusion of ketamine vs add-on riluzole: results from a 4-week, double-blind, placebo-controlled study. Neuropsychopharmacology 37:1526-1533.
29. Insel TR, Wang PS (2009) The STAR∗D trial: revealing the need for better treatments. Psychiatr Serv 60:1466-1467.
30. Jernigan CS, Goswami DB, Austin MC, Iyo AH, Chandran A, Stock-meier CA, Karolewicz B (2011) The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry 35:1774-1779.
31. Karege F, Perroud N, Burkhardt S, Schwald M, Ballmann E, La Harpe R, Malafosse A (2007) Alteration in kinase activity but not in protein levels of protein kinase B and glycogen syn-thase kinase-3beta in ventral prefrontal cortex of depressed suicide victims. Biol Psychiatry 61:240-245.
32. Kos T, Popik P, Pietraszek M, Schafer D, Danysz W, Dravolina O, Blokhina E, Galankin T, Bespalov AY (2006) Effect of 5-HT3 receptor antagonist MDL 72222 on behaviors induced by keta-mine in rats and mice. Eur Neuropsychopharmacol 16:297-310.
33. Krystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R (2003) NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology (Berl) 169:215-233.
34. Krystal JH, Perry EB Jr, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D'Souza DC (2005) Comparative and interactive human psychophar-macologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985-994.
35. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkil-inc N (2002) Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct 20:171-175.
36. Lally N, Nugent AC, Luckenbaugh DA, Ameli R, Roiser JP, Zarate CA (2014) Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression. Transla-tional psychiatry 4:e469.
37. Li N, Lee B, Liu RJ, Banasr M, Dwyer JM, Iwata M, Li XY, Aghajanian G, Duman RS (2010) mTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists. Science 329:959-964.
38. Li N, Liu RJ, Dwyer JM, Banasr M, Lee B, Son H, Li XY, Aghajanian G, Duman RS (2011) Glutamate N-methyl-D-aspartate receptor antagonists rapidly reverse behavioral and synaptic defcits caused by chronic stress exposure. Biol Psychiatry 69:754-761.
39. Liu RJ, Fuchikami M, Dwyer JM, Lepack AE, Duman RS, Aghajanian GK (2013) GSK-3 inhibition potentiates the synaptogenic and antidepressant-like effects of subthreshold doses of keta-mine. Neuropsychopharmacology 38:2268-2277.
40. Machado-Vieira R, Andreazza AC, Viale CI, Zanatto V, Cereser V, Jr., da Silva Vargas R, Kapczinski F, Portela LV, Souza DO, Salvador M, Gentil V (2007) Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci Lett 421:33-36.
41. Mantovani M, Pértile R, Calixto JB, Santos ARS, Rodrigues ALS (2003) Melatonin exerts an antidepressant-like effect in the tail suspension test in mice: evidence for involvement of N-methyl-d-aspartate receptors and the l-arginine-nitric oxide pathway. Neurosci Lett 343:1-4.
42. Monteggia LM, Gideons E, Kavalali ET (2013) The role of eukary-otic elongation factor 2 kinase in rapid antidepressant action of ketamine. Biol Psychiatry 73:1199-1203.
43. Nairn AC, Palfrey HC (1987) Identifcation of the major Mr 100, 000 substrate for calmodulin-dependent protein kinase III in mammalian cells as elongation factor-2. J Biol Chem 262:17299-17303.
44. Omata N, Chiu CT, Moya PR, Leng Y, Wang Z, Hunsberger JG, Leeds P, Chuang DM (2011) Lentivirally mediated GSK-3beta silencing in the hippocampal dentate gyrus induces antide-pressant-like effects in stressed mice. Int J Neuropsychop-harmacol 14:711-717.
45. Popik P, Kos T, Sowa-Kucma M, Nowak G (2008) Lack of persistent effects of ketamine in rodent models of depression. Psychop-harmacology (Berl) 198:421-430.
46. Sarkar S, Krishna G, Imarisio S, Saiki S, O'Kane CJ, Rubinsztein DC (2008) A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin. Hum Mol Genet 17:170-178.
47. Silva R, Mesquita AR, Bessa J, Sousa JC, Sotiropoulos I, Leao P, Almeida OF, Sousa N (2008) Lithium blocks stress-induced changes in depressive-like behavior and hippocampal cell fate: the role of glycogen-synthase-kinase-3beta. Neurosci-ence 152:656-669.
48. Tsuji S, Morinobu S, Tanaka K, Kawano K, Yamawaki S (2003) Lithium, but not valproate, induces the serine/threonine phos-phatase activity of protein phosphatase 2A in the rat brain, without affecting its expression. J Neural Transm 110:413-425.
49. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG (2001) Regulation of elongation factor 2 kinase by p90(RSK1) and p70 S6 kinase. EMBO J 20:4370-4379.
50. Yasuda S, Liang MH, Marinova Z, Yahyavi A, Chuang D-M (2009) The mood stabilizers lithium and valproate selectively activate the promoter IV of brain-derived neurotrophic factor in neurons. Mol Psychiatry 14:51-59.
51. Zarate CA Jr, Singh JB, Carlson PJ, Brutsche NE, Ameli R, Lucken-baugh DA, Charney DS, Manji HK (2006) A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 63:856-864.
52. Zhou W, Dong L, Wang N, Shi JY, Yang JJ, Zuo ZY, Zhou ZQ (2014) Akt Mediates GSK-3beta phosphorylation in the rat prefrontal cortex during the process of ketamine exerting rapid antidepressant actions. Neuroimmunomodulation 21:183-188.
53. Zuo DY, Wu YL, Yao WX, Cao Y, Wu CF, Tanaka M (2007) Effect of MK-801 and ketamine on hydroxyl radical generation in the posterior cingulate and retrosplenial cortex of free-moving mice, as determined by in vivo microdialysis. Pharmacol Bio-chem Behav 86:1-7.